NCT03211416 - Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

March 7, 2023

Study Completion Date

December 7, 2025

Conditions

Advanced Adult Hepatocellular CarcinomaChild-Pugh Class AStage III Hepatocellular CarcinomaStage IIIA Hepatocellular CarcinomaStage IIIB Hepatocellular CarcinomaStage IIIC Hepatocellular CarcinomaStage IV Hepatocellular CarcinomaStage IVA Hepatocellular CarcinomaStage IVB Hepatocellular Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

60611

Robert H Lurie Comprehensive Cancer Center, Chicago

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER